ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
To compare combination treatment of aripiprazole plus valproate versus valproate alone in the
prevention of relapse in bipolar I disorder patients with symptomatic remission after 5-6
weeks open-label acute treatment with aripiprazole plus valproate for manic or mixed episode,
with or without psychotic features.